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Optimal Angioplasty Versus Primary Stenting (OPUS)
W. DOUGLAS WEAVER, MD, FACC
HENRY FORD HOSPITAL, DETROIT, MICHIGAN
Despite the enormous popularity of stents, their superiority
over balloon angioplasty has never been demonstrated. Four
hundred seventy-nine patients scheduled for percutaneous
revascularization were randomized to either primary stent-
ing or a strategy of initial balloon angioplasty followed by
provisional stenting only when necessary. Seventy percent of
the patients had single-vessel disease; 99% of patients in the
primary stenting arm received a stent, compared with 37%
in the provisional stenting arm. After six months, the
combined incidence of death, myocardial infarction (MI)
and target vessel revascularization was significantly reduced
from 14.9% in the provisional stenting arm to 6.1% in the
primary stenting arm (p 5 0.003). Nearly all the difference
was due to a reduction in the rate of target vessel revascu-
larization (10% vs. 4%). Differences between the two groups
became evident at two months. For the initial procedure,
primary stenting was about $1,000 more expensive. By six
months, however, the total costs for primary stenting were
slightly less expensive than the costs for provisional stenting.
Commentary. This trial adds to the body of evidence
that argues in favor of routine stent use in appropriate
vessels. The study also emphasizes an extremely low rate of
target vessel revascularization, particularly in the primary
stenting group. The low rate of clinical events over the first
six-month follow-up rendered primary stenting a less ex-
pensive approach than potential stenting. Application of the
results of this study to clinical practice must be made with
recognition that the arteries studied were 3 mm or more in
diameter, 20 mm or less in length and with either mild or no
calcification.
Fast Revascularization During Instability in Coronary
Artery Disease (FRISC II): An Early Invasive Versus Early
Noninvasive Strategy in Unstable Coronary Artery Disease
LARS WALLENTIN, MD, PHD
UNIVERSITY HOSPITAL, UPPSALA, SWEDEN
The value of an early invasive treatment of patients with
acute coronary syndromes has been controversial. In this
first presentation from the FRISC II group, 2,433 patients
with unstable coronary disease were randomized after 48 h
to an invasive strategy consisting of catheterization followed
by revascularization within seven days, or a noninvasive
strategy in which patients underwent angiography only if
they had a positive exercise test, refractory or severe isch-
emia or MI. All patients were treated with aspirin, beta-
adrenergic blocking agents and the low molecular weight
heparin (dalteparin) until revascularization in the invasive
group and for at least five days in the noninvasive group.
At six months, the rate of death or MI was reduced by
21% from 12% in the noninvasive group and 9.5% in the
invasive group (p 5 0.045). Among men, the invasive
strategy resulted in a highly significant 34% reduction in the
combined end point (p 5 0.002) and a significant 52%
reduction in mortality from 3.2% to 1.5% (p 5 0.03).
Among women, there was no evidence of a beneficial effect
with an invasive strategy. In men as well as in women, there
was an approximately 50% reduction in symptoms of angina
and need for readmissions during the six-month follow-up.
Only 14% of patients in the noninvasive group underwent
angiography during the first six days of hospitalization. By
six months, however, 48% had undergone angiography. At
six months, the revascularization rate was 38% in the
noninvasive group versus 78% in the invasive group.
Commentary. This study fuels the debate over conser-
vative versus invasive treatment of acute coronary syndromes.
Unlike the Veterans Affairs Non–Q-Wave Infarction Strat-
egies In-Hospital (VANQWISH) and Thrombolysis in
Myocardial Infarction (TIMI) trials, the results of this trial
argue in favor of an invasive approach. Like the
VANQWISH trial, the FRISC II trial had a large number
of crossovers in the conservative group (revascularization
rate of 38%), but in this case, the crossovers do not detract
from the results.
Two other intriguing results of this trial were an ex-From the Emory Heart Center, Atlanta, Georgia.
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tremely low mortality rate in both groups and the lack of
benefit of the invasive strategy in women. Could the low
mortality rate speak to a benefit of five to seven days of
antithrombotic therapy before invasion as applied in this
study, or were the FRISC II patients relatively more stable
than in other studies? The lack of benefit to women poses
the same questions that are usually raised—specifically, were
women seen later in the course of disease, were they older,
did they have more comorbid factors such as diabetes, or
was the size of the coronary arteries a deciding factor?
The ADMIRAL Study: Abciximab With Percutaneous
Transluminal Coronary Angioplasty (PTCA) and Stent in
Acute Myocardial Infarction (AMI)
GILLES MONTALESCOT, MD, PHD
PITIE-SALPETRIERE HOSPITAL, PARIS, FRANCE
The role of abciximab in the setting of AMI has not yet
been fully tested. Three hundred patients with AMI were
randomized to either abciximab or placebo before undergo-
ing PTCA or stent implantation. More patients in the
abciximab group had a history of MI (14.8% vs. 8%). At
24 h, the TIMI-3 flow rates were 86% in the abciximab
group and 78% in the placebo group (p , 0.05). Left
ventricular function was higher in the abciximab group than
in the placebo group at 24 h (55% vs. 51%; p , 0.05).
The primary end point of the trial, the combined inci-
dence of death, recurrent MI and urgent target vessel
revascularization at 30 days, was reduced by 46.5% from
20% in the placebo group to 10.7% in the abciximab group
(p , 0.03). The individual components of the end point all
favored abciximab: death was reduced from 4.7% to 3.3%,
recurrent MI from 4.7% to 2% and urgent target vessel
revascularization from 14% to 6% (p 5 0.03).
The rate of major bleeding at 30 days was not signifi-
cantly higher in the abciximab group (4% vs. 2.6%), but a
significant increase in minor bleeding was observed (6.7%
vs. 1.3%; p 5 0.02).
Commentary. The accumulated data supporting the
benefit of coupling abciximab with thrombolytics or angio-
plasty in the treatment of AMI is rather convincing. This
study adds to those data. The improved TIMI-3 flow at
24 h with abciximab should convert to improved myocardial
preservation, and indeed, left ventricular function at 24 h
was better in the abciximab group. In addition, the use of
abciximab ensured better short-term stability (30-day inci-
dence of death, recurrent MI and urgent target vessel
revascularization was reduced). The major reluctance to
using abciximab has been concern about hemorrhagic com-
plications. The ADMIRAL study results should help allay
these concerns.
The Evaluation of Xemilofiban in Controlling Thrombotic
Events (EXCITE) Trial: 30-Day and Six-Month Results
WILLIAM W. O’NEILL, MD, FACC
WILLIAM BEAUMONT HOSPITAL, ROYAL OAK, MICHIGAN
Following the success of the intravenous glycoprotein IIb/
IIIa inhibitors, great hope has been held for oral formula-
tions of these drugs. In the largest prospective, randomized
trial ever performed in interventional cardiology, 7,262
patients undergoing percutaneous coronary revasculariza-
tion were randomized to placebo, low-dose or high-dose
xemilofiban, an oral IIb/IIIa inhibitor. Twelve percent of
patients presented with MI; the rest were evenly divided
between stable and unstable angina. More than two-thirds
of the patients received a stent.
At six months, the rate of death, nonfatal MI or urgent
revascularization, the primary end point of the trial, was
13.6% for placebo, 14.1% for low-dose and 12.6% for
high-dose xemilofiban-treated patients, a difference that did
not achieve statistical significance. There was a trend toward
a reduction in the rate of MI in the high-dose xemilofiban
group and a slight but troublesome trend toward an excess
of deaths and MI in the low-dose xemilofiban group.
In the first two days there was a significant reduction in
events in the active treatment groups, but this finding was
offset by an increase in events between day 2 and day 14. In
a subgroup analysis, diabetic patients appeared to benefit
from xemilofiban.
Commentary. Although the EXCITE trial will be dis-
missed as a negative study and will persuade the pharma-
ceuticals industry not to release this agent, the benefit of
treatment seen during the first two days should not be
dismissed. What does this fact tell us about the glycoprotein
IIb/IIIa inhibitors (dosage, delivery or tolerance) or the
pathophysiology of angioplasty? The unique benefit of this
class of platelet inhibitors in diabetics seen in this study
echoes previous studies of these drugs.
Randomized Comparison of Percutaneous Myocardial
Revascularization (PMR) Versus Medical Therapy:
Six-Month Outcome (Potential Angina Class Improvement
From Myocardial Channels/PACIFIC Trial)
STEPHEN N. OESTERLE, MD, FACC
MASSACHUSETTS GENERAL HOSPITAL, BOSTON, MASSACHU-
SETTS
Transmyocardial laser revascularization has emerged in
recent years as an important palliative therapy for severe
angina patients who are ineligible for revascularization. A
percutaneous version of this procedure, using a yttrium
aluminum garnet laser system developed by Cardiogenesis,
was studied in the PACIFIC study. Two hundred twenty-
one patients with class III or class IV angina on maximal
medical therapy and with evidence of reversible ischemia
were randomized to PMR or medical therapy.
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The PACIFIC trial was a one-year study. An interim
six-month analysis showed that 70% of the patients treated
with PMR had class 0 to 2 angina at six months, compared
with less than 15% in the control group. Half of the PMR
patients had an improvement of at least two classes in their
angina classification, compared with only 6% of patients in
the control arm. At six months, PMR patients had a 30%
increase in their exercise time, compared with a 5% im-
provement in the control group.
In the PMR group, there was one death at 29 days and
one case of tamponade requiring pericardiocentesis. There
were no periprocedural MIs or strokes.
Commentary. The results of the PACIFIC study should
be viewed as encouraging, but not convincing, in terms of
PMR’s benefits. First, the number of patients studied is
relatively small. Second, the presentation was an interim
analysis at six months. Furthermore, the patients were not
blinded to treatment modality, so the placebo effect on the
improvement of angina classification in the PMR group
must be considered. Finally, the 30% improvement in
exercise time converts to only an additional 120 s in
walking. Although this improvement is impressive, an
unblinded observer can easily lengthen exercise time.
LATE-BREAKING CLINICAL TRIALS I:
CARDIAC THERAPEUTICS
Should We Emergently Revascularize Occluded Coronary
Arteries for Cardiogenic Shock (SHOCK) Trial—An
International Randomized Trial of Emergency
PTCA/Coronary Artery Bypass Graft (CABG):
Results of the SHOCK Trial
JUDITH S. HOCHMAN, MD, FACC
ST. LUKE’S-ROOSEVELT HOSPITAL CENTER, NEW YORK,
NEW YORK
Core Laboratory Angiographic Findings, Angioplasty Results
and Relation to Treatment Effect: Results From the
Randomized SHOCK Trial
TIMOTHY A. SANBORN, MD, FACC
CORNELL MEDICAL CENTER, NEW YORK, NEW YORK
Although cardiogenic shock is the single largest cause of
death among patients hospitalized for AMI, the best treat-
ment strategy for this extremely vulnerable population has
never been determined. Three-hundred-two patients with
cardiogenic shock within 36 h of AMI were randomized to
a strategy of emergency revascularization (ERV) or a strat-
egy of initial medical stabilization (IMS). Balloon pump
support was encouraged in both arms, and thrombolysis was
strongly encouraged in the IMS patients.
Ninety-seven percent of patients assigned to ERV had
coronary angiography, and 87% were revascularized. Forty-
nine percent of the 152 ERV patients had PTCA 0.9 h after
randomization, and 38% had CABG 2.7 h after random-
ization.
The 30-day mortality rate, the primary end point of the
trial, was 46.7% in the ERV group versus 56% in the IMS
group. This 17% reduction in relative risk was not statisti-
cally significant. Preliminary analysis of an important sec-
ondary end point, six-month mortality, found a significant
benefit of ERV compared with IMS (54% vs. 65%, p 5
0.04).
Subgroup analysis found that those patients under 75
years of age experienced the most benefit of ERV. The
six-month mortality rate for patients under 75 was 48% in
the ERV group versus 69% in the IMS group.
Commentary. The SHOCK trial confirms that cardio-
genic shock after an AMI carries a very high mortality.
Unfortunately, the study did not find that ERV significantly
reduced the 30-day mortality. Preliminary analysis of six-
month mortality coupled with a favorable trend at 30 days,
however, suggests that the strategy of ERV should not yet
be forsaken, particularly in patients younger than 75 years.
The hope is that physicians would continue to approach
this condition in an investigative manner without conviction
that one or the other approach is best and that the issue will
be resolved only by continued investigation.
Fragmin and Early Revascularization During Instability
in Coronary Artery Disease (FRISC II)
LARS WALLENTIN, MD, PHD
UNIVERSITY HOSPITAL, UPPSALA, SWEDEN
The role of low molecular weight heparins used to treat
unstable coronary disease is unclear. In this second presen-
tation from the FRISC II group, patients with unstable
coronary disease received open-label dalteparin, a low mo-
lecular weight heparin, for at least five days or until
scheduled early revascularization. Patients were then ran-
domized to either continued dalteparin or placebo for three
months.
The primary objective concerned the efficacy of continued
dalteparin versus placebo in the 2,105 patients handled with
a noninvasive treatment strategy. In this comparison there
were no significant differences between the dalteparin and
placebo groups in the rate of death or MI at three months,
the prespecified end point (6.7% in the dalteparin group vs.
8% in the placebo group; p 5 0.2). In a post-hoc analysis,
however, the investigators found a significant reduction in
events at 45 days in the dalteparin group (3.7% vs. 6.7%;
p 5 0.003). Serious bleeds occurred more often in the
dalteparin group than in the placebo group (4.1% vs. 1.7%).
There were five intracranial hemorrhages in the dalteparin
group and none in the placebo group.
Drug assignment did not significantly alter the outcome
in the portion of the trial in which patients were randomized
to an invasive or a noninvasive treatment strategy. In the
invasive arm, the rate of death or MI at six months was 9.8%
in the placebo group and 9.2% in the dalteparin group. In
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the noninvasive arm, the rate was 12.7% in the placebo
group and 11.5% in the dalteparin group.
Commentary. This second portion of the FRISC II
study should be interpreted to show no benefit of long-term
(three months) use of low molecular weight heparin in
patients with unstable angina. Furthermore, the long-term
use carries an increased risk of bleeding. The benefit of
administering low molecular weight heparin for a short
duration and the lack of an added benefit by its more
prolonged use seems to be in accord with the pathophysi-
ology of unstable angina. Perhaps the only unresolved issue
is the correct interval for “short-duration” heparin therapy.
Multicenter Unsustained Tachycardia Trial (MUSTT)
ALFRED E. BUXTON, MD, FACC
TEMPLE UNIVERSITY SCHOOL OF MEDICINE, PHILADELPHIA,
PENNSYLVANIA
This trial was conducted to assess the role of electro-
physiologic (EP) studies in guiding antiarrhythmic ther-
apy. Seven-hundred-four patients with coronary artery
disease, nonsustained ventricular tachycardia, left ven-
tricular ejection fractions less than 40% and inducible
sustained ventricular tachycardia were randomized to
standard treatment or EP-guided antiarrhythmic therapy.
In the EP-guided group, patients first received type IA
drugs, propafenone or sotalol. After failing at least one
antiarrhythmic drug, patients were eligible to receive
another antiarrhythmic drug or an implantable cardio-
verter defibrillator (ICD). Patients in the EP-guided arm
were evenly divided between drug therapy and the ICD.
Patients in both groups received beta-blockers and
angiotensin-converting enzyme (ACE) inhibitors when
there were no contraindications.
The rate of arrhythmic death or cardiac arrest was
significantly reduced in the EP arm at 24 months (12% vs.
18%) and at 60 months (25% vs. 32%). A trend toward a
reduction in overall mortality was also observed.
In a post-hoc analysis, the entire beneficial effect in the
EP-guided group was found to occur in the group of
patients who received the ICD. No beneficial effects were
found in the patients who received antiarrhythmic drugs.
Reductions in total mortality were also found only in the
EP-guided patients who received the ICD.
Commentary. The results of the MUSTT should be
very troubling to physicians. The study rather conclusively
demonstrates that there is therapy available (ICD implan-
tation) that significantly reduces mortality in a given subset
of patients (coronary artery disease, nonsustained ventricular
tachycardia, left ventricular ejection fraction less than 40%
and inducible ventricular tachycardia).
The troubling issue is how we in the cardiology commu-
nity will apply this expensive therapy on a national scale in
a subset of patients with reduced long-term survival despite
this therapy. The study again demonstrates the inefficacy of
antiarrhythmic drugs in these patients.
Metoprolol CR/XL Randomized Intervention Trial in Heart
Failure (MERIT-HF)
AKE HJALMARSON, MD
SAHLGRENSKA HOSP-OSTRA, GOTEBORG, SWEDEN
Beta-blockers are rapidly becoming standard therapy for the
treatment of heart failure. In the MERIT-HF trial, 3,991
heart failure patients in Europe and the U.S. were random-
ized to placebo or metoprolol. Most of the patients were in
New York Heart Association class II (41%) or class III
(55%); two-thirds of patients had ischemic heart disease.
Metoprolol was started at either 12.5 mg or 25 mg/day and
titrated upward on a weekly basis to between 100 mg and
200 mg/day for an average daily dose of 159 mg. Background
usage of ACE inhibitors, diuretics and digitalis was very high.
In the metoprolol group, 14% of patients discontinued their
medication, compared with 15.5% in the placebo group.
At one year, total mortality was reduced by 34%, from
11% in the placebo group to 7.2% in the metoprolol group
(p 5 0.0062). The two groups began to diverge after three
months of treatment. Cardiovascular deaths were reduced
by 38%, sudden death by 41% and death due to progressive
heart failure by 49%.
The beneficial effects of metoprolol were consistent across
all subgroups, regardless of age, gender, etiology of heart
failure or presence or absence of diabetes, hypertension or
previous MI.
Commentary. The MERIT-HF is an important study
that conclusively establishes the benefit of selective beta-
blockers in reducing mortality in patients with heart failure.
It is important to note the consistency of benefit across all
subgroups. The results of this study should place beta-
blockers in the class of standard therapy for class II or III
heart failure. The lack of class IV patients in the study leaves
the use of beta-blockers in this functional class unanswered.
Furthermore, notation should be made that these beneficial
effects were obtained with relatively high doses of the drug.
The exact mechanism of mortality remains undefined, because
the drug lowered both sudden death and death by heart failure.
LATE-BREAKING CLINICAL TRIALS II:
CORONARY ARTERY DISEASE
Assessment of the Safety and Efficacy of a New Thrombolytic:
TNK-tPA Trial (ASSENT-2)
FRANS VAN DE WERF, MD, FACC
UNIVERSITY HOSPITAL GASTHUISBERG, LEUVEN, BELGIUM
Two new thrombolytic agents—variants of the well-
established tPA molecule—have now completed large clin-
ical trials. In the first thrombolytic mega-trial presented at
the American College of Cardiology 48th Annual Scientific
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Session, 16,950 patients with AMI were randomized to
either tPA or TNK-tPA, a mutant form of tPA with
increased fibrin specificity that can be administered as a
single-bolus injection.
The 30-day mortality rate was nearly identical in the two
groups: 6.16% in the TNK-tPA group and 6.18% in the
tPA group. The overall stroke rates were 1.78% and 1.66%,
respectively. The rates of intracerebral hemorrhage also
were very close: 0.93% and 0.94%, respectively. TNK-tPA
treatment resulted in a significant reduction in mild to
moderate bleeding complications (26% vs. 28.1%, p 5
0.002).
With one exception, there were no significant differences
among subgroups. In patients treated more than 4 h after
the onset of symptoms, mortality was 7.04% in the TNK-
tPA group versus 9.19% in the tPA group.
Designed as an equivalence trial, ASSENT-2 successfully
demonstrated that TNK-tPA did not cause a clinically
significant excess in events.
Commentary. The large number of patients required to
establish that a new thrombolytic agent is superior to tPA
has led to the equivalency trials, such as ASSENT-2 and
Intravenous n or tPA for Treatment of Infarcting Myocar-
dium Early (InTime-II). If the two agents can be estab-
lished as essentially equal, then the physician’s choice of
agent may depend on ease of delivery, cost or possible
benefit in a subgroup of patients. A comparison of the
results of the two studies does suggest that the presence of
increased fibrin specificity of a thrombolytic agent may
confer a measure of protection from the hemorrhagic
complications of thrombolysis.
A Phase III Trial of Novel Bolus Thrombolytic Lanoteplase
(nPA): InTime-II
KARL-LUDWIG NEUHAUS, MD
STAEDTISCHE KLINKEN, KASSEL, GERMANY
In this second thrombolytic mega-trial presented at the
American College of Cardiology 48th Annual Scientific
Session, 15,078 patients were randomized on a 1:2 basis to
either tPA or lanoteplase, a tPA mutant that is somewhat
less fibrin specific than tPA and that can be administered as
a single-bolus injection.
At 30 days, the rate of death was very similar in the two
groups: 6.6% in the tPA group versus 6.77% in the lanote-
plase group. Although the overall stroke rate was not
significantly elevated in the lanoteplase group (1.52% in the
tPA group vs. 1.89% in the lanoteplase group), the rate of
intracerebral hemorrhage was increased in the lanoteplase
group (0.62% vs. 1.13%, p 5 0.003).
Major and moderate bleeding complications occurred
equally in both groups; however, there were more mild
bleeding complications in the lanoteplase group than in the
tPA group (19.6% vs. 14.7%, p , 0.001).
Like the ASSENT-2 study, InTime-II was designed as
an equivalence trial and succeeded in demonstrating that
lanoteplase was equivalent to tPA with respect to mortality.
Commentary. The large number of patients required to
establish that a new thrombolytic agent is superior to tPA
has led to the equivalency trials, such as ASSENT-2 and
InTime-II. If the two agents can be established as essen-
tially equal, then the physician’s choice of agent may depend
on ease of delivery, cost or possible benefit in a subgroup of
patients. A comparison of the results of the two studies does
suggest that the presence of increased fibrin specificity of a
thrombolytic agent may confer a measure of protection from
the hemorrhagic complications of thrombolysis.
Gruppo Italiano Per Lo Studio Della Sopravvivenza
Nell’Infarto (GISSI) Prevention Study
FRANCO VALAGUSSA, MD
MARIO NEGRI INSTITUTE, MILAN, ITALY
The protective effects of fish oil supplements and vitamin E
have been long debated. Within three months of an MI,
11,324 patients were randomized to an n-3 polyunsaturated
fatty acid (PUFA) supplement (1 g daily), a vitamin E
supplement (300 mg daily), both or neither. Baseline
therapy included antiplatelet therapy in 90% of patients,
beta-blockers in 40%, and ACE inhibitors in 50%.
At 42 months’ follow-up, patients who received n-3
PUFA had a significant 10% relative risk reduction in the
combined rate of death plus nonfatal MI and nonfatal stroke
compared with those who did not receive n-3 PUFA (12.4%
vs. 13.7%, p 5 0.045). In contrast, treatment with vitamin
E caused a nonsignificant 4.7% relative risk reduction in the
combined end point. All of the beneficial effects of n-3
PUFA were due to a 20% reduction in the risk of death.
There were no significant interactions between the two
treatments. Both treatments were well tolerated. Gastroin-
testinal intolerance was the most commonly reported side
effect.
Commentary. The GISSI Prevention Study demon-
strates a vascular protective effect of fish oil supplements in
patients with coronary atherosclerosis. Previous studies have
demonstrated discordant results on atherosclerosis in terms
of fish and fish oil consumption on coronary artery disease.
Perhaps the difference in results relates to appropriate
dosage or to the end points measured. For example, whether
the beneficial effect is on plaque progression or thrombus
prevention would be a strong determinant of the appropriate
end points to be measured.
The study did not confirm the reduction in the risk of
cardiovascular death and nonfatal MI noted in the Cam-
bridge Heart Antioxidant Study (CHAOS). The difference
in GISSI and CHAOS is a lower dose of vitamin E in
GISSI (300 mgm vs. 400 to 800 mgm). Furthermore,
CHAOS, unlike GISSI, did include strokes as an end point.
The questions posed by these results revolve around whether
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there is a critical dose (greater than 300 mgm) of vitamin E
necessary for the beneficial effect, whether the addition of
strokes changes the results or whether the larger study
exposes fallacy in the smaller study.
Effects of ACE Inhibition and/or Lipid Lowering on
Coronary Atherosclerosis: The Simvastatin/Enalapril
Coronary Atherosclerosis Trial (SCAT)
KOON K. TEO, PHD, FACC
UNIVERSITY OF ALBERTA, EDMONTON, CANADA
This angiographic trial sought to determine the effects of a
cholesterol-lowering “statin” and an ACE inhibitor, sepa-
rately and in combination, on the progression of coronary
artery disease in patients with normal cholesterol levels. In a
2 3 2 factorial design, 460 coronary artery disease patients
were randomized to enalapril, simvastatin, both or neither.
Coronary angiography was performed at baseline and at 48
months.
Simvastatin, but not placebo, caused a significant reduc-
tion in total cholesterol and low-density lipoprotein choles-
terol levels. In addition, simvastatin, but not placebo, slowed
the rate of progression of atherosclerosis by nearly 50%, as
measured by quantitative coronary angiography. Enalapril
had a neutral effect on lipids and on the progression of
atherosclerosis. There were no significant interactions be-
tween enalapril and simvastatin.
For clinical events, enalapril therapy was associated with
a significant reduction in the combined rate of death, MI or
stroke, whereas simvastatin caused a significant reduction in
the rate of angioplasty procedures.
Commentary. This trial was primarily a confirmation of
previous studies. The effects of simvastatin on total choles-
terol and low-density lipoprotein cholesterol were predicted
by the results of the 4-S study. The effect of lipid lowering
on the progression of atherosclerosis was noted previously in
the Familial Atherosclerosis Treatment Study (FATS).
In terms of clinical events, the Survival and Ventricular
Enlargement (SAVE) trial demonstrated the reduction in
fatal and nonfatal cardiovascular events by ACE inhibition
and, again, 4-S demonstrated a reduction in coronary
intervention by use of simvastatin. This study did not show
a significant interaction between the two drugs, which is not
particularly surprising.
Sodium-Proton Exchange Inhibition With Cariporide in
Patients at Risk of Necrosis: Main Results of the Guard
During Ischemia Against Necrosis (GUARDIAN) Trial
PIERRE THEROUX, MD, FACC
MONTREAL HEART INSTITUTE, MONTREAL, CANADA
Cariporide is a novel agent that inhibits the sodium–
hydrogen exchange system, which plays a central role in cell
necrosis following ischemia. This study randomized 11,590
patients at high risk for ischemia to one of three doses of
cariporide or placebo. Patients were included if they had
unstable angina or non–Q-wave MI or were undergoing
high-risk angioplasty or high-risk bypass surgery.
The rate of death or MI at 36 days—the primary end
point of the trial—was 13.4% in the placebo group, 13.5%
in the low-dose group, 14.1% in the mid-dose group and
12.2% in the high-dose group. The 10% reduction in the
high-dose group did not achieve statistical significance, and
a clear dose–response relationship was not observed.
There were no significant differences between the 45% of
patients in the trial who were enrolled because they had an
acute coronary syndrome and the 30% of patients who
underwent angioplasty. However, among the 25% of pa-
tients who had bypass surgery, there was a significant
reduction in events in the high-dose cariporide group
(16.7% for placebo vs. 12.8% for high-dose cariporide).
Furthermore, the incidence of Q-wave MI was reduced in
all entry diagnostic groups. The drug was well tolerated and
was not associated with an increase in serious side effects.
Commentary. The GUARDIAN trial addresses a new
component of the ischemic process. The study fails to
establish the efficacy of cariporide, an inhibitor of the
sodium–hydrogen exchange system. Although there was a
significant reduction in ischemic events in patients under-
going high-risk bypass surgery after receiving cariporide,
such results of subgroup analysis should receive further
scrutiny and study before being accepted.
Double-Blind, Placebo-Controlled Trial of Recombinant
Human Vascular Endothelial Growth Factor (VEGF):
VEGF in Ischemia for Vascular Angiogenesis (VIVA) Trial
TIMOTHY D. HENRY, MD, FACC
HENNEPIN MEDICAL CENTER, MINNEAPOLIS, MINNESOTA
Administering VEGF is one of many approaches now being
explored to induce angiogenesis in patients with peripheral
and coronary disease. In this trial, 178 patients with severe
angina who were considered ineligible for mechanical re-
vascularization were randomized to placebo or one of two
doses of VEGF, administered as a 20-min intracoronary
infusion followed by 4-h intravenous infusions on days 3, 6,
and 9.
There were no significant differences among the groups
in the treadmill exercise time at 60 days—the primary end
point of the trial. Exercise time increased in all three groups:
by 43 s in the placebo group, 26 s in the low-dose VEGF
group and 32 s in the high-dose VEGF group. Similarly,
there were no significant differences among the groups in
the change in angina classification. Results at 120 days are
not yet available.
Treatment with VEGF appeared to be safe and well
tolerated. Two deaths, both in the placebo group, occurred
in the trial. Similarly, three placebo patients, but no VEGF
patients, developed cancer.
Commentary. It is difficult and probably inappropriate
to place much emphasis on this study showing no benefit of
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VEGF. The number of patients was small, the primary end
point of the study is relatively imprecise and the follow-up
was short. Angiogenesis is an exciting approach to ischemic
disease, whose most effective method of induction is yet to
be defined.
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Fibrinogen Receptor Occupancy Study (FROST) Trial:
Safety and Preliminary Efficacy of a One-Month Treatment
With Lefradafiban in Patients With Unstable Angina
ROBERT G. WILCOX, MD
UNIVERSITY OF NOTTINGHAM, UNITED KINGDOM
This trial was designed to study the safety and preliminary
efficacy of one-month treatment with lefradafiban, an oral
IIb/IIIa inhibitor. Lefradafiban is a pro-drug that is con-
verted in the body to fradafiban, which can be administered
intravenously.
More than 500 patients with unstable angina were
randomized to receive placebo or one of three doses of
lefradafiban for up to one month. The high-dose group was
discontinued by the data and safety monitoring committee
due to excessive bleeding complications. At one month,
more than 50% of patients in both the active treatment and
placebo groups had withdrawn from treatment. The largest
number of withdrawals were a result of patients proceeding
to a revascularization procedure, but adverse events in-
creased as the dose of lefradafiban was increased. Few
bleeding events were major, but lefradafiban caused a
significant, dose-related escalation in bleeding events.
At 30 days, the rate of death, MI and any event requiring
intervention was 33% in the placebo group, 31% in the
low-dose lefradafiban group, 22% in the mid-dose lefrada-
fiban group and 25% in the high-dose lefradafiban group.
Commentary. Like the EXCITE trial, the FROST trial
does not establish a benefit for the long-term (30-day)
administration of oral IIb/IIIa inhibitors. Furthermore, this
study demonstrates an increase in bleeding events associated
with the use of the drug.
Orbofiban in Patients With Unstable Coronary Syndromes
(OPUS)-TIMI 16 Trial
CHRISTOPHER P. CANNON, MD, FACC
BRIGHAM & WOMEN’S HOSPITAL, BOSTON, MASSACHU-
SETTS
This was the first large, phase III trial of an oral IIb/IIIa
inhibitor in patients with acute coronary syndromes. The
study randomized 10,302 patients to placebo, 50 mg b.i.d.
orbofiban throughout the trial, or 50 mg b.i.d. orbofiban for
30 days followed by 30 mg b.i.d. orbofiban.
The trial was originally intended to enroll 12,000 patients
but was stopped prematurely due to increased mortality at
30 days in one of the two treatment arms. The mortality rate
at 30 days was 1.4% in the placebo group, 2.3% in the
orbofiban 50/30 group and 1.6% in the orbofiban 50/50
group.
The primary end point of the trial, the 30-day combined
rate of death, MI, ischemic events requiring revasculariza-
tion or hospitalization or stroke, was 10.7% in the placebo
group, 9.7% in the orbofiban 50/30 group and 9.3% in the
orbofiban 50/50 group, representing an 11% reduction in
the combined orbofiban groups. This difference failed to
achieve statistical significance. Most of the benefits in the
orbofiban groups were due to reductions in urgent revascu-
larizations.
The same pattern was evident at 300 days follow-up, with
an excess of deaths in the orbofiban-treated groups partly
offset by a reduction in urgent revascularizations. Orbofiban
therapy was associated with a significant increase in the risk
of bleeding, including major or severe bleeding. Analysis of
the cause of deaths in the trial suggested that the excess
deaths seen with orbofiban may have been due to new
thrombotic events. Certain subgroups (patients without
heart failure or those with normal renal function) showed no
excess mortality and greater benefit, suggesting that these
groups deserve further study in future trials of this class of
drugs.
Commentary. The accumulated data of the OPUS-
TIMI 16, EXCITE and FROST trials speak rather con-
vincingly against the long-term (30-day) use of any oral
IIb/IIIa inhibitor. The 30-day administration of these
agents seems to offer no benefit in terms of reduction of
ischemic events and poses a risk for bleeding complications.
The suggestion that the excess deaths seen with orbofiban is
due to new thrombotic events is puzzling.
Clopidogrel Aspirin Stent International Cooperative Study
(CLASSICS) Trial
MICHEL E. BERTRAND, MD, FACC
HOSPITAL OF CARDIOLOGY, LILLE, FRANCE
Ticlopidine and aspirin are standard anticoagulant therapy
for stent implantation. Clopidogrel has been proposed as an
agent that may be as effective as ticlopidine but without
causing some of the adverse events associated with ticlopi-
dine.
In addition to receiving aspirin for 28 days, 1,020 patients
undergoing stent implantation were randomized for 28 days
to daily ticlopidine, 75 mg clopidogrel daily or a 300-mg
loading dose of clopidogrel on day 1 followed by a daily
75 mg dose. The primary end point of the trial was the
combined incidence at 28 days of major bleeding, neu-
tropenia, thrombocytopenia or early discontinuation of
the study drug. The composite end point was reduced
from 9.1% in the ticlopidine group to 6.3% in the
clopidogrel 75 group and to 2.9% in the clopidogrel
300/75 group.
Nearly all of the difference in the combined end point was
due to a lower rate of early discontinuation of therapy in the
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clopidogrel groups. The chief causes of discontinuation in
the ticlopidine group were allergic reactions and gastroin-
testinal or skin disorders.
Commentary. This study confirms the experience of
many U.S. cardiologists. The surprising finding is that
patients receiving the loading dose of clopidogrel had
significantly fewer side effects than those receiving only the
maintenance dose. It is hoped that the published study will
comment on the comparative effectiveness of the agents in
terms of preventing stent thrombosis and will offer an
explanation for the paradox of a larger dose of a drug
causing fewer side effects.
Reprint requests and correspondence: Dr. D. C. Morris, Emory
Heart Center, Suite A2200, 1365 A Clifton Road, Atlanta,
Georgia 30322.
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